OS Therapies reports 71.2% three-year survival versus 45.8% historical control
AI Summary- OS Therapies released interim three-year survival data from its Phase 2b OST-HER2 study.
- 71.2% of OST-HER2-treated patients were alive at three years, versus 45.8% in historical controls.
- OS Therapies earmarked tax credits for a U.K. confirmatory Phase 3 trial.